Neuropathic Pain – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Neuropathic Pain – Pipeline Review, H2 2019’, provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain

– The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects

– The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neuropathic Pain”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“1st Bio Therapeutics Inc

Abalone Bio Inc

Achelios Therapeutics Inc

Acorda Therapeutics Inc

Adynxx Inc

AfaSci Inc

Affectis Pharmaceuticals AG

Akelos Inc

Algiax Pharmaceuticals GmbH

Algomedix Inc

Alion Pharmaceuticals Inc

Allergan Plc

Allodynic Therapeutics LLC

AlphaNavi Pharma Co Ltd

Amgen Inc

AnaBios Corp

Anavex Life Sciences Corp

Andros Pharmaceuticals Co Ltd

Angelini Group

AngioChem Inc

Anida Pharma Inc

AnyGen Co Ltd

AOBiome LLC

Aoxing Pharmaceutical Company Inc

APT Therapeutics Inc

Aptarion biotech AG

Aptinyx Inc

Aquilus Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Asahi Kasei Pharma Corp

Asarina Pharma AB

Astellas Pharma Inc

Astraea Therapeutics LLC

AstraZeneca Plc

Astrocyte Pharmaceuticals Inc

AusCann Group Holdings Ltd

Avanir Pharmaceuticals Inc

Avilex Pharma ApS

Axsome Therapeutics Inc

BCI Pharma SA

Bioasis Technologies Inc

Biodol Therapeutics SAS

BioElectron Technology Corp

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Bioiberica SAU

Blackthorn Therapeutics Inc

Bol Pharma

Bsense Bio Therapeutics Ltd

Calchan Ltd

Cara Therapeutics Inc

Cavion LLC

CCH Pharmaceuticals ApS

CDA Research Group Inc

Celgene Corp

Cellatoz Therapeutics Inc

Centrexion Therapeutics Corp

Cerecin Inc

Cerecor Inc

CerSci Therapeutics Inc

Charleston Laboratories Inc

Chromocell Corp

Circuit Therapeutics Inc

Citragen Pharmaceuticals Inc

Cleveland Diabetes Care Inc

Clexio Biosciences Ltd

Coda Biotherapeutics Inc

Corium International Inc

Crossject SA

Cryno LLC

CrystalGenomics Inc

Curatis AG

CURx Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daya Drug Discoveries Inc

DelNova Inc

Dompe Farmaceutici SpA

Eicosis LLC

Eli Lilly and Co

EnhanX Biopharm Inc

Epalex Corp

Exodos Life Sciences Limited Partnership

Expression Drug Designs LLC

Exxel Pharma Inc

Four Chuankeruide Pharmaceutical Co Ltd

GABA Therapeutics Inc

GB Sciences Inc

Glialogix Inc

Grace Therapeutics LLC

Grunenthal GmbH

GW Pharmaceuticals Plc

H. Lundbeck AS

Hana Pharm Co Ltd

Helixmith Co Ltd

Hoba Therapeutics ApS

ICE Therapeutics Ltd

Ichnos Sciences Inc

Imbrium Therapeutics LP

Immune Pharmaceuticals Inc

Impel NeuroPharma Inc

Initiator Pharma AS

InKemia IUCT Group SA

InMed Pharmaceuticals Inc

InStar Technologies AS

Intec Pharma Ltd

Integral Molecular Inc

IntelGenx Corp

Intellipharmaceutics International Inc

Invisio Ltd

Ionis Pharmaceuticals Inc

Ipsen SA

iQure Pharma Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

JT Pharmaceuticals Inc

Kancera AB

KannaLife Sciences Inc

Kineta Inc

Klaria Pharma Holding AB

Knopp Biosciences LLC

Kolon Life Science Inc

Komipharm International Co Ltd

Krisani Bio Sciences Pvt Ltd

Lateral Pharma Pty Ltd

Lexicon Pharmaceuticals Inc

Living Cell Technologies Ltd

Lohocla Research Corp

Luye Pharma Group Ltd

MannKind Corp

Mapi Pharma Ltd

MD Biosciences GmbH

Medifron DBT Co Ltd

MEDRx Co Ltd

Medytox Inc

Merck & Co Inc

Merz Pharma GmbH & Co KgaA

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Mundipharma International Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeurAxon Pharma Inc

Neurim Pharmaceuticals Ltd

Neuro Vigor LLC

NeuroCycle Therapeutics GmbH

Neurodyn Life Sciences Inc

NeuroFix Therapeutics LLC

Neurona Therapeutics Inc

NeurOp Inc

NeuroPn Therapeutics LLC

NeuroTherpia Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

NoNO Inc

Novaremed AG

Novassay SA

Noveome Biotherapeutics Inc

NutriBand Inc

OKYO Pharma Ltd

Old API Wind-down Ltd

OliPass Corporation

OliX Pharmaceuticals Inc

Orexigen Therapeutics Inc

OWP Pharmaceuticals Inc

Panag Pharma Inc

Panaxia Pharmaceutical Industries Ltd

Paracelsus Neuroscience I LLC

Patagonia Pharmaceuticals LLC

Pharmaleads SA

Pharmnovo AB

Phosphagenics Ltd

Pivot Pharmaceuticals Inc

PixarBio Corp

PlantForm Corp

Priavoid GmbH

PRISM Pharma Co Ltd

Promius Pharma LLC

ProNeurogen Inc

Qingdao Chia Tai Haier Pharmaceutical Co Ltd

RAFT Pharmaceuticals

RaQualia Pharma Inc

Re-Pharm Ltd

Regeneus Ltd

Relieve Genetics Inc

Revance Therapeutics Inc

Romark Laboratories LC

Rottapharm Biotech Srl

Saniona AB

Sarfez Pharmaceuticals Inc

Satsuma Pharmaceuticals Inc

Scientus Pharma Inc

Scilex Holding Co

Serentrix LLC

Seurat Therapeutics Inc

Shanghai Junshi Bioscience Co Ltd

Shanghai SIMR Biotech Co Ltd

Shenox Pharmaceuticals LLC

Shin Nippon Biomedical Laboratories Ltd

Shionogi & Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Signal Pharma Ltd

Sollis Therapeutics Inc

Sorrento Therapeutics Inc

Sosei Heptares

SpineThera Inc

Stem Cell Medicine Ltd

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Synerkine Pharma BV

Syntrix Biosystems Inc

Techfields Pharma Co Ltd

Terran Biosciences Inc

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Titan Pharmaceuticals Inc

Topical Innovations BV

Toray Industries Inc

Trevena Inc

TrioxBio Inc

Vertex Pharmaceuticals Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Winston Pharmaceuticals Inc

Xalud Therapeutics Inc

Xoc Pharmaceuticals Inc

Yantai YenePharma Co Ltd

Yooyoung Pharm Co Ltd

Yuhan Corp

Zosano Pharma Corp”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Neuropathic Pain Overview 10

Neuropathic Pain Therapeutics Development 11

Neuropathic Pain Therapeutics Assessment 37

Neuropathic Pain Companies Involved in Therapeutics Development 54

Neuropathic Pain Drug Profiles 103

Neuropathic Pain Dormant Projects 412

Neuropathic Pain Discontinued Products 431

Neuropathic Pain Product Development Milestones 436

Appendix 446

List of Tables

“List of Tables

Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by 1st Bio Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Abalone Bio Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Achelios Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Acorda Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Adynxx Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AfaSci Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Affectis Pharmaceuticals AG, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Akelos Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Algiax Pharmaceuticals GmbH, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Algomedix Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Alion Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Allergan Plc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Allodynic Therapeutics LLC, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AlphaNavi Pharma Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Amgen Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AnaBios Corp, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Anavex Life Sciences Corp, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Angelini Group, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AngioChem Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Anida Pharma Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AnyGen Co Ltd, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AOBiome LLC, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by APT Therapeutics Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Aptarion biotech AG, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Aptinyx Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Aquilus Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Araim Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Arena Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Artelo Biosciences Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Asahi Kasei Pharma Corp, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Asarina Pharma AB, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Astellas Pharma Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Astraea Therapeutics LLC, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AstraZeneca Plc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by AusCann Group Holdings Ltd, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Avanir Pharmaceuticals Inc, H2 2019

Neuropathic Pain (Neuralgia) – Pipeline by Avilex Pharma ApS, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports